CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.

FDA fast track designation enables increased regulatory interaction and potential rolling BLA review for RPTR-1.201 in ...

A team led by Prof. HU Zheng from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences (CAS), in collaboration with international researchers, has unveiled a ...

Polyclonal antibodies are produced when different B-cell clones in the immune system respond to the same antigen. It produces a variety of antibodies that can bind to different sites on that antigen.

Orca-T demonstrated superior cGVHD-free survival and lower nonrelapse mortality compared to standard allo-HSCT in the Precision-T trial. The immunotherapy utilizes a mix of hematopoietic stem cells, ...

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and ...